Published in Gastroenterology on March 01, 2001
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol (2005) 1.35
Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci (2008) 1.28
Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis (2002) 1.27
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol (2013) 1.23
Mimicry and deception in inflammatory bowel disease and intestinal behçet disease. Gastroenterol Hepatol (N Y) (2012) 1.11
Behçet's disease. Arthritis Res Ther (2003) 1.07
Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis? Yonsei Med J (2016) 1.03
Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med (2007) 1.01
Update on the therapy of Behçet disease. Ther Adv Chronic Dis (2014) 1.01
Gastrointestinal Behçet's disease: a review. World J Gastroenterol (2015) 1.00
Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol (2006) 0.95
Perspectives for TNF-alpha-targeting therapies. Arthritis Res (2002) 0.88
Adamantiades-Behcet's disease-complicated gastroenteropathy. World J Gastroenterol (2012) 0.87
Diagnosis and management of intestinal Behçet's disease. Clin J Gastroenterol (2014) 0.87
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int (2009) 0.86
Elevated levels of tumor necrosis factor alpha (TNF-alpha) in human immunodeficiency virus type 1-transgenic mice: prevention of death by antibody to TNF-alpha. J Virol (2002) 0.83
Outcome predictors for intestinal Behçet's disease. Yonsei Med J (2013) 0.83
Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord (2003) 0.79
Ileocecal ulcers accompanied by relapsing polychondritis: a case report. Springerplus (2014) 0.79
Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. World J Gastroenterol (2013) 0.78
Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease. Case Rep Rheumatol (2015) 0.76
Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet's Disease: Eight Consecutive Cases. J Clin Med Res (2016) 0.76
Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report. BMC Gastroenterol (2013) 0.76
A rare manifestation of Behçet's syndrome: immunological correlates and successful treatment of an esophageal ulcer. Dig Dis Sci (2003) 0.76
Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators Inflamm (2017) 0.75
Intestinal Behçet and Crohn's disease: two sides of the same coin. Pediatr Rheumatol Online J (2017) 0.75
Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease. Intest Res (2017) 0.75
Assessment of clinical skills of residents utilizing standardized patients. A follow-up study and recommendations for application. Ann Intern Med (1991) 3.23
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology (1996) 3.08
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol (1997) 3.05
Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet (2000) 2.39
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol (2001) 2.36
Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther (2014) 2.06
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol (2000) 2.03
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis (2001) 1.77
Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol (2001) 1.72
CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology (2001) 1.48
Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology (1999) 1.45
Maternal occupational and hobby chemical exposures as risk factors for neural tube defects. Epidemiology (1999) 1.42
Demonstration of estrogen receptors by monoclonal antibody in formalin-fixed breast tumors. Lab Invest (1988) 1.06
Statistical association between cancer incidence and major-cause mortality, and estimated residential exposure to air emissions from petroleum and chemical plants. Environ Health Perspect (1984) 1.04
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant (2009) 1.04
Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab (2001) 1.00
Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther (2012) 0.99
Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). Endoscopy (2007) 0.97
The orthopedic aspects of the fetal alcohol syndrome. Clin Orthop Relat Res (1979) 0.97
Inhibition of adenosine 3',5'-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormone. Biochem Biophys Res Commun (1974) 0.94
Reaction of uracil and thymine derivatives with sodium bisulfite. Studies on the mechanism and reduction of the adduct. Biochim Biophys Acta (1976) 0.93
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol (2000) 0.90
Role of structural birth defects in preterm delivery. Paediatr Perinat Epidemiol (2001) 0.87
Diagnosis of hepatoma. J Nucl Med (1972) 0.84
Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut (2004) 0.82
Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis (2000) 0.81
"Virtual microscopy" and the internet as telepathology consultation tools: diagnostic accuracy in evaluating melanocytic skin lesions. Am J Dermatopathol (1999) 0.81
Inhibition of growth hormone and thyrotropin release by growth hormone-release inhibiting hormone. Mol Cell Endocrinol (1974) 0.81
beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol (2004) 0.81
Intrathecal methysergide antagonizes the antinociception, but not the hyperalgesia produced by microinjection of baclofen in the ventromedial medulla of the rat. Neurosci Lett (1998) 0.79
Maternal periconceptional use of electric bed-heating devices and risk for neural tube defects and orofacial clefts. Teratology (1999) 0.79
Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther (2003) 0.78
Lipoprotein(a) as a determinant of the severity of angiographically defined carotid atherosclerosis. QJM (1995) 0.78
Linear attenuation coefficients for compensator based IMRT. Australas Phys Eng Sci Med (2007) 0.78
Assessing combined chemical exposures as risk factors for neural tube defects. Reprod Toxicol (2001) 0.76
Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Dis Colon Rectum (1999) 0.75
Promotion and selling of unnecessary food supplements: quackery or ethical pharmacy practice? Am Pharm (1988) 0.75
Group psychotherapy treatment of borderline personalities. Int J Group Psychother (1999) 0.75
Synthesis of hypoxanthine, guanine, and 6-thiopurine nucleosides of 6-deoxy-D-allofuranose. J Med Chem (1983) 0.75
A community health nursing career: but I want to be where the action is! Imprint (1985) 0.75
Synthesis and antitumor activity of 7- and 9-(6'-deoxy-alpha-L-talofuranosyl) hypoxanthine and 9-(6'-deoxy-alpha-L-talofuranosyl)-6-thiopurine. J Med Chem (1983) 0.75
Phosphorous-containing analogues of aspartame. J Pharm Sci (1984) 0.75
Methylation versus ethylation of DNA in target and nontarget tissues of Fischer 344 rats treated with N-nitrosomethylethylamine. Cancer Res (1986) 0.75
Rupture of an aneurysmal pulmonary trunk 40 years after Blalock-Taussig anastomosis. Am J Cardiol (1988) 0.75
Proceedings: Ultrastructural changes at the synapse associated with depression of synaptic transmission in rat superior cervical ganglion after injury of post-ganglionic axons. J Physiol (1973) 0.75
Analogs of somatostatin. Part A. Chemistry and in vitro results. Curr Top Mol Endocrinol (1976) 0.75